

識別番号・報告回数	新凍結人血漿	報告日	第一報入手日 2008. 12. 16	新医薬品等の区分 該当なし	総合機構処理欄
一般的名称	新凍結人血漿	研究報告の公表状況	Benjamin RJ, Kline L, Dy BA, Kennedy J, Pisciotto P, Sapatnekar S, Mercado R, Eder AF. Transfusion. 2008 Nov;48(11):2348-55. Epub 2008 Jul 22.	公表国 米国	使用上の注意記載状況・ その他参考事項等 新鮮凍結血漿「日赤」 新鮮凍結血漿-LR「日赤」 血液を介するウイルス、 細菌、原虫等の感染 vCJD等の伝播のリスク
販売名(企業名)	新鮮凍結血漿「日赤」(日本赤十字社) 新鮮凍結血漿-LR「日赤」(日本赤十字社)	研究報告の概要	<p>○全血由来血小板の細菌汚染:米国赤十字(ARC)の初流血除去および保存前プール培養検査の導入背景:全血由来血小板(WBP)輸血後の細菌性敗血症は、現在も患者にとって大きなリスクであり、これは細菌汚染の抑制あるいは検出するための実用的、効果的な方法がないことが主な原因である。我々は、WBPと初流血除去後のプール全血由来血小板(PSP)の敗血症反応リスクおよび細菌培養結果について報告する。</p> <p>試験デザインおよび方法:Acrodose PLシステム(Pall Medical)で調べた製品適合および品質管理(QC)について、4つの地域血液センターにて評価を行った。細菌汚染リスクは、報告されたWBPによる敗血症輸血反応の調査および自動化細菌検出システム培養(BacT/ALERT 3D, bioMérieux)を用いた白血球除去PSPの好気QC培養により評価した。</p> <p>結果:PSP実施前(2003年1月~2006年12月)には2,535,043単位のWBPが供給され、死亡2例を含む敗血症反応20例の報告があった(敗血症反応:100万あたり0.77[1:126,752]、死亡:100万あたり0.79[1:1,267,522])。2006年10月にPSPが導入され製品適合率は99.6%となり、1プールのPLT数は平均4.0×10^{11}であった。実施トライアル中に初流血除去技術を用いた全血採血セットが導入され、PSP細菌培養の確定陽性率は100万あたり2,111(1:474)から965(1:1036)に減少した(オッズ比0.46;95%信頼区間0.22~0.95)。供給されたPSP 25,936単位による敗血症反応は報告されなかった。</p> <p>結論:初流血除去および細菌培養は、WBP輸血の細菌リスクを低減させる有効な方法である。PSPの細菌汚染率は、同等の培養プロトコルを用いたARCの現在のアフェレーシスPLTの5.8倍であると評価された。</p>		
報告企業の意見	全血由来血小板の細菌汚染リスクを低減させるためには、初流血除去および細菌培養によるスクリーニングが有効な方法であるとの報告である。	今後の対応	<p>日本赤十字社では、輸血による細菌感染予防対策として、すべての輸血用血液製剤を対象に保存前白血球除去及び初流血除去を導入している。さらに、輸血情報リーフレット等により細菌感染やウイルス感染について医療機関へ情報提供し注意を喚起しているほか、細菌感染が疑われる場合は対応を周知している。今後も細菌やウイルスの検出や不活化する方策について情報の収集に努める。</p>		

37

BLOOD COMPONENTS

Bacterial contamination of whole blood-derived platelets: the introduction of sample diversion and prestorage pooling with culture testing in the American Red Cross

Richard J. Benjamin, Linda Kline, Beth A. Dy, Jean Kennedy, Patricia Pisciotto, Suneeti Sapatnekar, Rachel Mercado, and Anne F. Eder

BACKGROUND: Bacterial sepsis following whole blood-derived platelet (WBP) transfusion has remained a substantial patient risk, primarily due to a lack of practical and effective means to limit or detect bacterial contamination. We describe the risk of reported septic reactions to WBPs and the introduction of prestorage-pooled whole blood-derived platelets (PSPs) collected using initial sample diversion and cultured for bacterial contamination.

STUDY DESIGN AND METHODS: Product qualification and quality control (QC) testing with the Acrodose PL system (Pall Medical) were evaluated in four regional blood centers. Bacterial contamination risk was assessed by review of reported septic transfusion reactions to WBPs and by aerobic QC culture of leukoreduced PSPs utilizing automated microbial detection system cultures (BacT/ALERT 3D, bioMérieux).

RESULTS: Before implementing PSPs (January 2003-December 2006), we distributed 2,535,043 WBP units and received 20 reports of septic reactions including 2 fatalities (7.9 per million [1:126,752] reactions and 0.79 per million [1:1,267,522] fatalities). In October 2006, PSPs were effectively implemented with a product qualification success rate of 99.6 percent and a mean yield of 4.0×10^{11} platelets (PLTs) per pool. Whole blood collection sets with sample diversion technology were introduced during the operational trial and decreased the rate of confirmed-positive bacterial culture of PSPs from 2111 (1:474) to 965 (1:1036) per million (odds ratio, 0.46; 95% confidence interval, 0.22-0.95). No septic reactions to PSPs were reported (25,936 PSP units distributed).

CONCLUSION: Sample diversion and bacterial culture are effective methods to reduce bacterial risk with WBP transfusion. Bacterial contamination of PSPs was assessed at 5.8-fold our current rate for apheresis PLTs utilizing comparable culture protocols.

The introduction of the Food and Drug Administration (FDA)-approved Acrodose PL system (Pall Medical, East Hills, NY) for producing prestorage-pooled, leukoreduced whole blood-derived platelets (PSPs) now offers the possibility of quality control (QC) bacterial culture testing of whole blood-derived platelets (WBP) at the blood center, utilizing either the eBDS (Pall Medical) or the BacT/ALERT 3D (bioMérieux, Durham, NC) culture systems.^{1,2} In addition to providing a means to screen WBPs, the Acrodose PL system offers the potential advantages of eliminating the time and labor needed for point-of-issue pooling at the hospital transfusion service and reducing outdate rates, because PSPs do not evoke a 4-hour outdate after pooling. PSPs, however, carry a disadvantage that confirmatory and indeterminate culture results lead to the discard of not only the final pooled product, but also to the retrieval and discard of all the associated red blood cell (RBC) and plasma products from the original whole blood

ABBREVIATIONS: PSP(s) = prestorage-pooled whole blood-derived platelet(s); WBP(s) = whole blood-derived platelet(s).

From the National Headquarters, American Red Cross, Washington, DC; the Jerome H. Holland Laboratory, American Red Cross, Rockville, Maryland; the Connecticut Region, American Red Cross, Farmington, Connecticut; and the Northern Ohio Region, American Red Cross, Cleveland, Ohio.

Address reprint requests to: Richard J. Benjamin, MD, PhD, American Red Cross Blood Services, National Headquarters, 2025 E Streets NW, Washington, DC 20006; e-mail: BenjaminR@USA.Redcross.org.

RJB is a consultant to Immucor, Inc., and Cerus Corp. The authors attest that they have no conflicts of interest with respect to this study.

Received for publication April 25, 2008; revision received May 24, 2008; and accepted May 26, 2008.

doi: 10.1111/j.1537-2995.2008.01853.x
TRANSFUSION 2008;48:2348-2355.

collections, because the single implicated WBP component in the pool is generally not identified. Limiting the initial bacterial contamination of each WBP component in the pool therefore is critical and expected to occur with optimized skin preparation techniques and initial whole blood diversion at collection.^{3,4}

In this report we describe the baseline risk of sepsis associated with transfusion of WBPs, as measured by the rate of septic transfusion reactions reported to the American Red Cross Hemovigilance Program in 2003 through 2006.⁵ After successful implementation of PSPs at four American Red Cross regional blood centers, we assess the impact of sample diversion on the risk of contamination during collection and document the ability of culture testing to identify contaminated products and prevent their release into inventory.

MATERIALS AND METHODS

Whole blood was collected into collection sets with or without a sample diversion system (Leukotrap-RCPL, Pall Medical) from routine blood donors in four American Red Cross Blood Services Regions (A-D). The time frame for the introduction of PSPs and whole blood collection utilizing sample diversion strategies overlapped, such that the first 5211 PSPs were manufactured with WBP that lacked sample diversion. The phlebotomy site was prepared by our standard, FDA-recommended, skin disinfection protocol utilizing povidone-iodine scrubs (or chlorhexidine gluconate in 70% isopropyl alcohol scrubs for donors allergic to iodine)⁶ throughout the study. Leukoreduced WBP concentrates were prepared and stored at 20 to 24°C. After a minimum of 24 hours, five ABO-identical WBP concentrates were pooled into a 1.5-L CLX storage bag (Acrodose PL System, Pall Medical) by means of multiple sterile connections (TSCD or SCD sterile tube welders, Terumo Medical Corp., Elkton, MD). Pools were labeled D+ if there was one or more D+ WBP unit in the pool.

An 8-mL sample for bacterial testing was removed from the storage bag using a platelet (PLT) sampling device (SampLok sampling kit, IFL, Reston, VA; or accessory sampling assembly, Gambro BCT, Lakewood, CO). An additional 1.5 to 2 mL was used for product qualification testing (PLT count, pH). PLT yield was calculated from the PLT concentration and the volume of the PSPs.

At the start of the evaluation of the Acrodose PL system, process control testing was performed. PLT yield, concentration and product volume, sterility by bacterial culture, and pH were determined and success was defined by our standard process control procedures. This entailed testing the first 60 pools with no failures or 91 pools with one allowable failure. pH testing was performed for 60 pools by determining the pH of 40 PSPs at issue, 10 PSPs on Day 5, and 10 PSPs at outdate; for 90 pools: by deter-

mining pH of 61 PSPs at issue, 15 PSPs on Day 5 and 15 PSPs at outdate. After successfully completing process control, monthly QC testing of 1 percent of PSPs was initiated.

Detection of bacterial contamination

An automated microbial detection system (BacT/ALERT 3D, bioMérieux) was used for aerobic cultures, with bottle inoculation performed in a laminar-flow hood, as previously described.^{5,8} PSPs were released into inventory for distribution after at least 12 hours with negative culture results, and cultures were monitored until product outdate on Day 5. All components associated with positive initial culture results were quarantined or retrieved if already distributed to transfusion services. A second 8-mL sample was taken from the initially positive PSPs and/or cocomponents and inoculated into a new aerobic bottle for confirmatory culture. The initial and subsequent positive culture bottles were sent to independent microbiology laboratories for bacterial isolation and identification. Bacterial culture test results were classified according to AABB Bulletin 04-07⁹ with further subcategorization as follows: A confirmed-positive result is a true-positive result with the growth of the *same organism* in the initial and confirmatory sample; a false-positive result is a positive bottle signal but a negative result on subsequent culture. False-positive results were further characterized as either possible sampling contamination, if bacteria were detected in the initial bottle but not the confirmatory culture, or instrument error, if the initial culture bottle was found to be sterile.⁶ If PLT components were not available for confirmatory culture because they were transfused or destroyed during the manufacturing process, the initial-positive signal could not be resolved and the results were classified as "indeterminate." Occasions where an initial-positive culture was detected but the subsequent confirmatory culture revealed a different bacterial isolate were labeled "discrepant." In the AABB classification, these cases would be included in the "true-positive" category.

Septic transfusion reactions

All septic transfusion reactions reported to the 35 regional American Red Cross blood centers were investigated and compiled in a centralized database through the American Red Cross Hemovigilance Program, as previously described.⁵ Clinical criteria for a possible septic transfusion reaction to apheresis PLTs were any of the following symptoms within 4 hours of transfusion: fever of 39°C or greater or a change of 2°C or more from pretransfusion value, rigors, tachycardia greater than 120 bpm or a change of 40 bpm or more from pretransfusion value, or a change of more than 30 mm Hg in systolic or diastolic blood pressure.¹⁰ A definite septic transfusion reaction

fulfilled the clinical criteria and yielded the same bacterial species from the residual PSP component and the patient. A probable septic transfusion reaction fulfilled the clinical criteria but was associated with a positive culture on the residual component without a matching positive blood culture result in the recipient. Transfusion reactions that did not meet the criteria of probable or definite septic reactions were excluded.

Statistical analysis

Odds ratios (ORs) and 95 percent confidence intervals (CIs) were computed to compare the odds of contamination before and after the implementation of sample diversion strategies.¹¹ Differences between groups were significant at p value of less than 0.05. The American Red Cross Institutional Review Board determined that the operational trial was exempt under 45CFR46, 21CFR50.

RESULTS

Baseline risk of bacterial sepsis from WBPs before implementation of PSPs

We assessed the baseline risk of bacterial sepsis with WBPs as reported to the American Red Cross Hemovigilance Program, before the introduction of PSPs and sample diversion. Between January 1, 2003, and December 31, 2006, the 35 American Red Cross blood regions distributed 2,535,043 WBP units and 20 septic reactions were reported, including 2 fatalities, for an overall rate of 7.9 per million (1:126,752) reactions and 0.79 per million (1:126,752) fatalities per distributed component (Table 1). Products involved in septic reactions were pooled at the transfusion service in a median pool size of 5 components (mean, 4.75; range, 2-8 components). The median calculated risk per transfused product, assuming that 5 products were pooled, was therefore 39.4 per million (1:253,350) for sepsis and 3.94 per million (1:253,350) for fatality.

Eight of the reported reactions fulfilled the criteria for definite septic reactions and 12 were probable septic reactions, because the incriminated organism was not cultured from the patient, either due to lack of blood culture testing (5 cases) or due to negative culture results for patients on antibiotic therapy (7 cases). The most common bacterial contaminants were likely commensal skin organisms (16 cases; 80%); 4 (20%) were likely enteric organisms (Table 1). The components that comprised each pool of WBPs were of uniform storage age, and 15 reactions occurred on Day 5 (75%), 3 on Day 4 (15%), 1 on Day 3 (5%), and 1 on Day 2 (5%) after collection. The two fatalities implicated *Staphylococcus aureus* and *Escherichia coli* and were transfused on Day 5 of storage.

TABLE 1. Bacteria implicated in septic transfusion reactions to WBPs distributed between January 1, 2003, and December 31, 2006

Bacterial isolate	Number of septic reactions
Coagulase-negative <i>Staphylococcus</i>	11
<i>S. aureus</i> *	2
<i>Staphylococcus</i> spp. (mixed culture)†	1
<i>Bacillus</i> spp.	1
<i>Corynebacterium</i> spp.	1
Likely skin contaminants (subtotal)	16
<i>S. bovis</i>	1
<i>E. coli</i> *	2
Multiple (<i>Klebsiella pneumoniae</i> , <i>E. coli</i>)	1
Likely enteric organisms (subtotal)	4
Total reactions	20
Number of WBP units distributed	2,535,043
Septic reactions, rate per 10 ⁶	7.9
Fatalities, rate per 10 ⁶	0.79

* Associated with a fatality.
† Coagulase-negative and coagulase-positive *Staphylococcus*.

Operational trial and implementation of PSPs

Because of the potential safety benefit of QC bacterial detection and other operational advantages, we implemented the Acrodose PL PSP system. In an initial operational trial, four regions of the American Red Cross manufactured 7628 PSP units, of which 5211 were produced before and 2417 after the implementation of whole blood collection sets with initial sample diversion. A pool size of 5 units was necessary to produce a consistent component containing more than 3 × 10¹¹ PLTs, as losses due to pooling and sampling for QC tests and bacterial culture amounted, on average, to 16.1 percent (range, 8.3%-31.5%) of the PLT yield. The pooling and sampling procedure was accomplished on average in 17.5 minutes (range, 13.5-21.3 min) once staff were fully trained and familiar with the technique.

All four regions successfully completed the phase of process control testing. Two regions had no failures in their first 60 pools and two regions had one failure in their first 91 pools (see *Guidance for Industry and FDA Review Staff Collection of Platelets by Automated Methods*, December 2007 for current criteria¹²). One failure was due to a high PLT concentration greater than 2300 × 10⁹ per µL, and the other, to PLT yield less than 2.2 × 10¹¹ per pool. Once process control was established, monthly QC testing was then initiated, involving pH testing between Day 2 and outdate, of at least 1 percent of PSPs or 4 PSP units per month if fewer than 400 pools were prepared. A total of 131 pools (all four regions) were tested over 2 to 6 months and 100 percent had pH values of 6.2 or greater within a range of 6.50 to 7.70.

The vast majority of PSPs had PLT yields equivalent to the minimum yield for plateletpheresis (i.e., ≥3.0 × 10¹¹; Table 2). The Acrodose PL system incorporates acceptance product qualification criteria that are determined by

TABLE 2. Product qualification data (±1 standard deviation) during the operation trial for the Acrodose PL system for PLTs pooled in four regions of the American Red Cross

Total pools: 7628	Region				Mean	Requirement
	A	B	C	D		
Number of pools	2224	4313	604	487	258 ± 13	180-420
Volume (mL)	253 ± 8	266 ± 10	232 ± 9	250 ± 6	1546 ± 220	≤2300
PLTs (×10 ⁹ /μL)	1547 ± 206	1530 ± 224	1647 ± 240	1548 ± 193	4.0 ± 0.6	2.2-5.8
Yield (×10 ¹¹)	3.9 ± 0.5	4.1 ± 0.6	3.8 ± 0.6	3.9 ± 0.5	97.60	
Pools ≥ 3.0 × 10 ¹¹ (%)	97.10	98.10	94.50	98.80	100	
pH ≥ 6.2* (%)	100	100	100	100	100	100
PLT qualification success (%)	99.96	99.56	98.68	100	99.60	

* Includes process control and monthly QC.

TABLE 3. Bacterial detection in PSPs before and after the implementation of sample diversion (SD)

Variable	Before SD		After SD		After SD vs. before SD OR (95% CI)
	Number	Rate per 10 ⁶	Number	Rate per 10 ⁶	
Pools	5,211		20,725		
Confirmed-positive	11	2111	20	965	0.46 (0.22-0.95)
False-positive (machine error)	3	576	8	386	0.67 (0.18-2.53)
False-positive (contamination)	5	960	6	290	0.30 (0.09-0.99)
Indeterminate	2	384	4	193	0.50 (0.09-2.75)
Discordant	0	0	2	97	ND
Total	21	4030	40	1930	0.48 (0.28-0.81)

ND = not determined.

the manufacturer for PLT yield (2.2 × 10¹¹ – 5.8 × 10¹¹ per pool), pool volume (180-240 mL), PLT concentration (<2.3 × 10⁶/μL), pH at the time of issue (≥6.2), and sterility (bacterial culture-negative). The product qualification success rate was 99.6 percent for pools manufactured during the operational trial (Table 2). Twenty-eight of 7628 pools failed, due to a concentration of greater than 2.3 × 10⁶ per mL (11 cases), a yield of less than 2.2 × 10¹¹ per pool (8 cases), or a yield of more than 5.8 × 10¹¹ per pool (14 cases; 5 pools failed on multiple criteria).

Sample diversion during collection of WBPs

The first 5211 PSP units were manufactured from collection sets lacking sample diversion and 21 products yielded an initial-positive result (4030 per million [1:248]; Table 3). In each case, the PSPs and all components (RBCs and plasma) were retrieved and destroyed if they had not yet been transfused. After the introduction of sample diversion, 20,725 pools were manufactured and tested by culture (during the operational trial and subsequent routine production until December 31, 2007). Only 40 of the 20,725 PSPs yielded an initial-positive culture result (1930 per million [1:518]) indicating a significant 52 percent reduction in the rate of bacterial contamination (OR, 0.48; 95% CI, 0.28-0.81). This reduction reflected a significant decrease associated with sample diversion in the rates of both confirmed-positive culture rates (2111 vs. 965 per million; OR, 0.46; 95% CI, 0.22-0.95) and false-

positive (contamination) rates (960 vs. 290 per million; OR, 0.30; 95% CI, 0.09-0.99), but not in the rates of indeterminate or false-positive samples due to machine error (Table 3). Most of the bacterial isolates in confirmed-positive cultures were likely skin flora (Table 4), and the rate of detection was significantly decreased after implementation of sample diversion (1727 vs. 724 per million; OR, 0.42; 95% CI, 0.18-0.96). The rate of detection for likely enteric organisms, however, did not change with sample diversion (384 vs. 241 per million; OR, 0.63; 95% CI, 0.12-3.24). All organisms detected as false-positive samples due to contamination were likely skin commensal organisms (Table 4).

PSPs with confirmed-positive or false-positive cultures were all successfully removed from inventory and not distributed for transfusion. Four pools with indeterminate culture results were transfused on Day 3 or Day 4 of storage, before the initial-positive culture was detected, but no adverse reactions to these components were reported.

DISCUSSION

Retrospective passive surveillance studies performed before the advent of screening cultures, initial sample diversion, and standardized skin preparations, revealed that the risk of a septic reaction with transfusion of WBPs ranged from 1:14,000 to 1:95,000.^{10,13,14} The data presented herein from the American Red Cross Hemovigilance

TABLE 4. Bacteria detection and time to initial culture-positive in PSPs before and after the introduction of sample diversion (SD)

Bacterial isolate	Confirmed-positive		False-positive (contamination)	
	Before SD* (5,211 pools)	After SD (20,725 pools)	Before SD (5,211 pools)	After SD (20,725 pools)
	Number (rate per 10 ⁶)	Number (rate per 10 ⁶)	Number (rate per 10 ⁶)	Number (rate per 10 ⁶)
Coagulase-negative Staphylococcus	1	13	3	4
<i>S. aureus</i>	1	1	1	2
Streptococcus spp. (β-hemolytic)	1	1	1	2
<i>Bacillus</i> spp.	1	1	1	2
<i>Corynebacterium</i> spp.	1	1	1	2
Likely skin contaminants	9 (1727)	15 (724)	2 (960)	6 (290)
<i>S. bovis</i>	1	1	1	2
<i>E. coli</i>	1	1	1	2
<i>Serratia marcescens</i>	1	1	1	2
<i>Proteus mirabilis</i>	1	1	1	2
<i>Enterococcus faecalis</i>	1	1	1	2
Likely enteric organisms	2 (384)	5 (241)	0	0
All isolates	11 (2111)	20 (965)	5 (960)	8 (290)

* SD = initial sample diversion.
† Mean time to a positive culture for all (before SD and after SD) coagulase-negative Staphylococcus confirmed-positive cultures was 17.5 hours and for all false-positive cultures was 27.2 hours.

Program provide an estimate derived from 2,535,043 distributed WBP units between January 1, 2003, and December 31, 2006, with 20 reports of sepsis after transfusion, including 2 fatalities. Assuming a mean pool size of 5 WBP components, we calculated a rate per distributed product of 39.4 per million (1:25,350) for sepsis and 3.94 per million (1:253,504) for septic fatality. A limitation of this approach is that the actual number of transfused PLT doses is not known with certainty. The 2005 National Blood Collection and Distribution Survey records that a mean of 18.1 percent of WBPs were discarded before use, further suggesting that the actual septic transfusion rate per transfusion was higher than documented here.¹⁵ Furthermore, several small studies and a large single-institution active surveillance study performed over 15 years have established that active surveillance may detect considerably more contaminated products and septic reactions than passive surveillance, supporting a higher actual contamination rate, currently estimated at 1:1000 to 1:3000 transfused products.^{16,17} For comparison, our published estimates of the risk of plateletpheresis samples tested by bacterial culture and distributed by the American Red Cross during the same period (2004-2006) was 1:74,807 for septic reactions and 1:498,711 for fatalities, suggesting that WBPs may have been associated with a greater bacterial risk than apheresis PLTs for each transfused dose.⁸ Similarly, the organisms involved in these reactions were mostly skin organisms; fatalities occurred predominantly on Day 5 of storage and frequently involved major pathogens.¹⁶

In an effort to improve the safety profile of WBPs, we successfully implemented and validated PSPs with the Acrodose PL system and sample diversion and demonstrated reduced contamination at the time of collection. Our preliminary experience suggested that the Acrodose PL system requires a significant investment in staff training and hands-on experience to optimize yields and to minimize QC losses (data not shown). We therefore performed an operational trial in four regions that routinely distribute WBPs. After successful production and distribution of 7628 PSPs over a 5-month period, we implemented PSPs for routine manufacture. We demonstrated the ability to consistently meet all of the manufacturers' quality variables for PSPs; indeed, 97.6 percent contained more than 3 × 10¹¹ PLTs and only 0.4 percent (28 of 7628 pools) of pools failed QC testing, either on yield or on PLT concentration variables.

For bacterial culture, we selected the bioMérieux Bact/ALERT 3D system rather than the Pall eBDS system, because the former approach allows greater culture sensitivity by testing 8-mL rather than 3- to 4-mL samples, allows product release into inventory at 12 hours rather than 24 to 36 hours after culture inoculation, and is consistent with our laboratory approach with apheresis PLTs.

Bacterial culture of 5211 PSPs before and 20,725 PSPs after the introduction of sample diversion at the time of collection revealed a significant reduction in the overall rate of initial positive samples, which was accounted for by a significant decrease in the rate of confirmed-positive and false-positive (contamination) cultures. In contrast, the rate of indeterminate cultures and false-positive cultures due to machine error were unchanged. Similar decreases in confirmed-positive cultures with sample diversion have been previously documented in WBPs.^{16,19} In our hands, sample diversion reduced the confirmed positive rates by 54 percent, from 2111 per million to 965 per million pools (OR, 0.46; 95% CI, 0.22-0.95) and the false-positive (contamination) rate by 70 percent from 960 per million to 290 per million pools (OR, 0.30; 95% CI, 0.09-0.99; Table 3).

Sample diversion technology likely reduces bacterial contamination by skin commensal bacteria mobilized during phlebotomy.^{3,20} Our finding (Table 4) that confirmed-positive cultures derived from skin commensal bacteria decreased from 1727 to 724 per million after the implementation of sample diversion (OR, 0.42; 95% CI, 0.18-0.96), while the rates of enteric contaminants were unchanged (384 vs. 241 per million; OR, 0.63; 95% CI, 0.12-3.24), supports this concept. The finding that false-positive cultures (contamination) were also significantly reduced supports our previously published hypothesis that some false-positive samples are likely due to components contaminated by low levels of bacteria that do not proliferate on PLT storage.²¹ In this view, a truly contaminated product that gives rise to an initial-positive culture is labeled a false-positive culture due to inadequate sampling during reculture of the product, such that the sample is sterile. Further evidence to support the hypothesis is provided by analyzing the time between culture inoculation and the initial positive test result. The most frequent species involved in false-positive (contamination) cultures is *Staphylococcus* (coagulase-negative), which took significantly longer to grow in false-positive than confirmed-positive cultures (mean, 27.2 hr vs. 17.5 hr; $p = 0.02$, t test; Table 4). This delay in growth may be ascribed to lower initial concentrations, prolonged lag phase of growth, or longer doubling times in culture, although the latter is less likely for a given species of bacteria.

PSP implementation required appropriate management of cocomponents associated with initial-positive cultures, directed by the culture results. After implementation of sample diversion, there were 40 initial-positive cultures of 20,725 pools tested (1930 per million [1:518]), and these products and their cocomponents were placed into hold quarantine; 14 of the initial-positive samples were shown to be false-positive samples and their cocomponents were released into inventory. The other positive culture results were associated with 130 RBCs and 130 plasma cocomponents that were retrieved and discarded

if they had not been transfused. Because only a single WBP component likely contaminated the pool but could not be isolated in retrospect as the source by the current procedure, approximately 80 percent of the destroyed cocomponents were likely sterile and acceptable for transfusion. The direct and indirect cost of these component losses represent a disadvantage of the Acrodose PL system and should be accounted for in the cost analysis of PSP manufacturing. Of the 20 confirmed-positive cultures after implementation of sample diversion, 15 (75%) were still skin commensal organisms, raising the possibility that further improvements in skin preparation may be effective at lowering contamination and mitigating the loss of cocomponents with PSP production. Two of the four enteric organism contaminants were *Streptococcus bovis*, a species that has been linked to colonic carcinoma, and the donors of these products were counseled to seek further medical investigation.²²

The confirmed-positive rate of 965 per million (1:1036) bacterial cultures of PSPs after the implementation of sample diversion is 5.2-fold greater than our published rate for apheresis PLTs of 185 per million (1:5399) collected between 2004 and 2006. In that report, the BacT/ALERT cultures were inoculated with 4-mL samples and only a proportion (~39%) of the products were collected with inlet line sample diversion strategies.⁵ We recently implemented universal inlet line sample diversion for plateletpheresis, doubled the BacT/ALERT sample volume to 8 mL, and report a confirmed-positive culture rate of 167 per million (1:5,922) after testing 431,490 collections (Table 5 and A.F. Eder et al., submitted for publication).

These data suggest that when utilizing a standardized protocol of skin preparation, sample diversion, and culture, a unit-per-unit comparison of PSPs and plateletpheresis reveals a 5.8-fold (OR, 5.8; 95% CI, 3.5-9.5) greater risk of confirmed-positive contamination for PSPs, suggesting that individual WBP and plateletpheresis collections carry a similar risk of contamination (given the pooling of 5 WBP products in PSPs). These data raise the possibility that PSPs may pose a greater risk of sepsis to transfusion recipients due to false-negative bacterial culture results, after pooling five components. Despite this theoretical risk, PSPs offer to supplement the available PLT inventory at relatively low cost and may mitigate the risk of some transfusion reactions (e.g., transfusion-related acute lung injury, immune hemolysis), due to lower plasma volume derived from individual donors. The counterargument that there may be greater risk from increased donor exposure will need careful evaluation.

Direct comparison of absolute PLT contamination rates assessed by different institutions is not possible, due to variations in sampling time, volume of sample, and conditions of culture (e.g., aerobic/anaerobic conditions). Nevertheless, in those institutions where WBP and

plateletpheresis collections were assessed utilizing a standard protocol, the relative contamination rates are informative. Our finding that individual WBPs are likely contaminated at similar rates as plateletpheresis collections is substantiated by the report of Kleinman and colleagues,⁷ who tested individual WBP and plateletpheresis products using the BacT/ALERT system and by Yomtovian and coworkers who tested pooled WBP and plateletpheresis products at issue using plate cultures¹⁷ (Table 5). In all three cases, the WBPs were manufactured using the PLT-rich plasma method. These results are in contrast to those reported from Europe, where WBPs are produced using the buffy coat technique: In these reports, prestorage-pooled buffy coat PLTs have the same confirmed-positive contamination rate as similarly tested plateletpheresis (Table 5).^{18,23,24} This difference has been ascribed to the overnight hold process in the manufacture of buffy coat PLTs, which may allow some bacteria to be inactivated by white cells before leukoreduction.²⁴

We remain aware of the continued, residual risk of sepsis from bacterially contaminated WBP units. In 2007, the American Red Cross distributed 381,884 single WBP components and received one report of a severe septic reaction to a single WBP unit transfused to an infant, in which coagulase-negative *Staphylococcus* was implicated after pulsed-field gel electrophoresis demonstrated identical isolates from both the patient and residual product. We received no reports of septic reactions to PSPs in 2006 or 2007, although a false-negative QC culture result in 1 of 543 PSPs tested was detected by a transfusion service using a culture-based point-of-issue test. In this case, the PSP unit was transfused on Day 4 without reaction, but a 1- to 2-mL sample of the PSPs collected at the time of issue grew coagulase-negative *Staphylococcus* on plate culture at a titer of 2×10^4 colony-forming units per mL (M. Jacobs and R. Yomtovian, personal communication, 2008).¹⁶

In summary, the successful implementation of Acrodose PL PLTs by the American Red Cross now provides an alternative source of QC-cultured PLTs for transfusion. PSPs undoubtedly present lower bacterial risk to patients than WBPs that are pooled at the point of issue and tested with non-FDA-approved surrogate tests, such as pH or glucose content. Ongoing hemovigilance for septic transfusion reactions, however, will be required to document the relative safety of PSPs considering their approximately 5.8-fold higher rate in detectable contamination compared to that of plateletpheresis.

ACKNOWLEDGMENTS

We would like to thank T. Donato, American Red Cross, Penn-Jersey Region; M. Gaughan, American Red Cross, North Central Region; G. Kotnik, American Red Cross, Northern Ohio Region; and P. Sundara, American Red Cross, Connecticut Region, for their hard work in ensuring the success of the Acrodose PL operational trial.

TABLE 5. Comparison of confirmed-positive bacterial contamination rates of apheresis and WBP-derived samples utilizing the PLT-rich plasma (PRP) or buffy coat (BC) methods^{7,17,23,24}

Study	PLT pool size	PLT preparation	WBPs		Apheresis PLTs		OR (95% CI)
			Products tested	Rate per million (95% CI)	Products tested	Rate per million (95% CI)	
This report	5	PRP	20,725	965 (942-1,368)	431,490	167 (158-205)	5.8 (3.5-9.5)
Kleinman et al. ⁷	1	PRP	13,579	74 (0-218)	21,914	46 (0-135)	NS
Yomtovian et al. ¹⁷	5	PRP	12,961	2,592 (1,590-3,234)	15,493	452 (117-787)	5.3 (2.3-12.0)
Schezenmiller et al. ²³	5	BC	22,044	726 (370-1,091)	15,198	655 (390-1,320)	NS
Murphy et al. ²⁴	5	BC	30,407	329 (125-593)	12,823	312 (6-618)	NS
de Korte et al. ¹⁸	5	BC	6,749	1,322 (997-2,519)	4,963	2,418 (1050-3,786)	NS

NS = not significant, $p \geq 0.05$.

REFERENCES

- Sweeney J, Kouttab N, Holme S, Cheves T, Nelson E. In vitro evaluation of pre-storage pools consisting of mixed A and O platelet concentrates. *Transfusion* 2007;47:1154-61.
- Sweeney JD, Kouttab NM, Holme S, Kuitis JD, Cheves TA, Nelson EI. Pre-storage pooled whole-blood-derived leuko-reduced platelets stored for seven days, preserve acceptable quality and do not show evidence of a mixed lymphocyte reaction. *Transfusion* 2004;44:1212-9.
- McDonald CP, Roy A, Mahajan P, Smith R, Charlett A, Barbara JA. Relative values of the interventions of diversion and improved donor-arm disinfection to reduce the bacterial risk from blood transfusion. *Vox Sang* 2004;86:178-82.
- McDonald CP, Lowe P, Roy A, Robbins S, Hartley S, Harrison JF, Slopecki A, Verlander N, Barbara JA. Evaluation of donor arm disinfection techniques. *Vox Sang* 2001;80:135-41.
- Eder AF, Kennedy JM, Dy B, Notari EP, Weiss JW, Fang CT, Wagner S, Dodd RY, Benjamin RJ, and the American Red Cross Regional Blood Centers. Bacterial screening of apheresis platelets and the residual risk of septic transfusion reactions: The American Red Cross experience (2004-6). *Transfusion* 2007;47:1134-42.
- Fang CT, Chambers LA, Kennedy J, Strupp A, Fucci MC, Janas JA, Tang Y, Hapip CA, Lawrence TB, Dodd RY, American Red Cross Regional Blood Centers. Detection of bacterial contamination in apheresis products: American Red Cross experience, 2004. *Transfusion* 2005;45:1845-52.
- Kleinman SH, Kamel HT, Harpool DR, Vanderpool SK, Custer B, Wilbank TB, Nguyen KA, Tomasulo PA. Two-year experience with aerobic culturing of apheresis and whole blood-derived platelets. *Transfusion* 2006;46:1787-94.
- Silva MA, Gregory KR, Carr-Greer MA, Holmberg JA, Kuehnert MJ, Brecher ME, Task Force. Summary of the AABB Interorganizational Task Force on Bacterial Contamination of Platelets: Fall 2004 impact survey. *Transfusion* 2006;46:636-41.
- AABB Bulletin #04-07. Actions following an initial positive test for possible bacterial contamination of a platelet unit. Bethesda (MD): American Association of Blood Banks; 2004.
- Kuehnert MJ, Roth VR, Haley NR, Gregory KR, Elder KV, Schreiber GB, Arduino MJ, Holt SC, Carson LA, Banerjee SN, Jarvis WR. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. *Transfusion* 2001;41:1493-9.
- Pezzullo JC. 2-way contingency table analysis [computer software]. c2006 [accessed 2006 Dec 1]. [cited May 24, 2008]. Available from: <http://www.statpages.org/ctab2x2.html>
- Food and Drug Administration. Guidance for industry and FDA review staff collection of platelets by automated methods. Rockville (MD): FDA; issued 12/17/2007 [cited May 24, 2008]. Available from: <http://www.fda.gov/cber/guidelines.htm>

- Perez P, Salmi LR, Follea G, Schmit JL, de Barbeyrac B, Sudre P, Salamon R, BACTHEM Group; French Haemovigilance Network. Determinants of transfusion-associated bacterial contamination: results of the French BACTHEM Case-Control Study. *Transfusion* 2001;41:862-72.
- Ness P, Braine H, King K, Barraso C, Kickler T, Fuller A, Blades N. Single-donor platelets reduce the risk of septic platelet transfusion reactions. *Transfusion* 2001;41:857-61.
- Whitaker BI, Sullivan M. The 2005 nationwide blood collection and utilization survey report. Bethesda (MD): Department of Health and Human Services; 2006.
- Jacobs MR, Good CE, Lazarus HM, Yomtovian RA. Relationship between bacterial load, septic virulence and transfusion reaction with transfusion of bacterially contaminated platelets. *Clin Infect Dis* 2008;46:1214-20.
- Yomtovian RA, Palavecino EL, Dysktra AH, Downes KA, Morrissey AM, Bajaksouzian S, Pokorny MA, Lazarus HM, Jacobs MR. Evolution of surveillance methods for detection of bacterial contamination of platelets in a university hospital, 1991 through 2004. *Transfusion* 2006;46:719-30.
- de Korte D, Curvers J, de Kort WL, Hoekstra T, van der Poel CL, Beckers EA, Marcellis JH. Effects of skin disinfection method, deviation bag, and bacterial screening on clinical safety of platelet transfusions in the Netherlands. *Transfusion* 2006;46:476-85.
- Bruneau C, Perez P, Chassaigne M, Allouch P, Audurier A, Gullian C, Janus G, Boulard G, De Micco P, Salmi LR, Noel L. Efficacy of a new collection procedure for preventing bacterial contamination of whole-blood donations. *Transfusion* 2001;41:74-81.
- de Korte D, Marcellis JH, Verhoeven AJ, Soeterboek AM. Diversion of first blood volume results in a reduction of bacterial contamination for whole-blood collections. *Vox Sang* 2002;83:13-6.
- Benjamin RJ, Wagner S. The residual risk of sepsis: modeling bacterial detection in a two bottle culture system and an analysis of sampling error. *Transfusion* 2007;47:1381-9.
- Haimowitz MD, Hernandez LA, Herron RM Jr. A blood donor with bacteraemia. *Lancet* 2005;365:1596.
- Schrezenmeier H, Walther-Wenke G, Muller TH, Weinauer F, Younis A, Holland-Letz T, Gels G, Asmus J, Bauerfeind U, Burkhardt J, Deitenbeck R, Förstemann E, Gebauer W, Höchsmann B, Karakassopoulos A, Liebscher UM, Säinger W, Schmidt M, Schunter F, Strelz W, Seifried E. Bacterial contamination of platelet concentrates: results of a prospective multicenter study comparing pooled whole blood-derived platelets and apheresis platelets. *Transfusion* 2007;47:644-52.
- Murphy WG, Foley M, Doherty C, Tierney G, Kinsella A, Salami A, Cadden E, Coakley P. Screening platelet concentrates for bacterial contamination: low numbers of bacteria and slow growth in contaminated units mandate an alternative approach to product safety. *Vox Sang* 2008;95:13-9. □

別紙様式第 2-1
番号 7

医薬品
医薬部外品
化粧品
研究報告 調査報告書

厚生労働省処理欄	使用上の注意記載状況 その他参考事項等		代表として静注用ヘパースプリン-III の記載を示す。 2. 重要な基本的注意 (1) 本剤の原材料となる血液については、HBs抗原、抗HCV抗体、抗HIV-1抗体、抗HIV-2抗体陰性で、かつALT (GPT) 値でスクリーニングを実施している。更に、プールした試験血漿については、HIV-1、HBV及びHCVについて核酸増幅検査 (NAT) を実施し、適合した血漿を本剤の製造に使用しているが、当該NATの検出限界以下のウイルスが混入している可能性が常に存在する。本剤は、以上の検査に適合した高力価の抗HBs抗体を含有する血漿を原料として、Cohnの低温エタノール分画で得た画分からポリエチレンテレフタレート (PET) 製のDEAEセファデックス処理等により抗HBs人免疫グロブリンを濃縮・精製した製剤であり、ウイルス不活化・除去を目的として、製造工程において60℃、10時間の液状加熱処理及びウイルス除去膜によるろ過処理を施しているが、投与に際しては、次の点に十分注意すること。
鑑別番号・報告回数	第一報入手日 2009年2月13日	新医薬品等の区分 該当なし	公衆衛生
一般的名称	報告日	研究報告の公表状況	公衆衛生 アメリカ
販売名 (企業名)	① 乾燥抗HBs人免疫グロブリン ② ポリエチレンテレフタレート処理抗HBs人免疫グロブリン ③ ヘパースプリン (パネシス) ④ 静注用ヘパースプリン-III (ハネシス)	CDC/AMWR 2009; 58 (5): 105-109	公衆衛生 アメリカ
研究報告の概要	カリフォルニア州において、Confidential Morbidity Reports (CMR) のデータのうち、2000-2007年の間のコクシオアイデス症の報告症例数および入院数の増加、ならびに最も高い罹患率について報告された。コクシオアイデス症は、土壌中の真菌である <i>Coccidioides immitis</i> または <i>Coccidioides posadasii</i> の浮遊胞子を吸い込むことによつて感染する。1995-2000年の間、カリフォルニア州でのコクシオアイデス症の報告症例数は、人口100,000人当たりで毎年平均2.5であった。しかし、2000-2006年の報告数は3倍を超え、人口100,000人当たり2.4から8.0に増加した。この増加を特徴付けるため、カリフォルニア州公衆衛生局は2000-2007年の症例および入院データ、ならびに2008年の予備的症例報告データを分析した。その結果の示すところによれば、2000-2006年の間の年間症例数は Kern 郡が最も高く (人口100,000人当たりで3.0から7.9に増加した)、カリフォルニア州のコクシオアイデス症の増加は隣のアリゾナ州および米国全体に観察された増加と類似している。アリゾナ州は毎年米国のコクシオアイデス症例全体の約60%を報告しており、1998年の1,812症例 (人口100,000人当たり37) から2006年の5,535症例 (人口100,000人当たり91) と実質的な増加を報告した。米国全体では、コクシオアイデス症報告症例数は1996年の1,697症例 (人口100,000人当たり0.64) から2006年の8,917症例 (人口100,000人当たり8.79) に増加した。コクシオアイデス症報告数が最近増加している理由については、十分に解明されていない。	今後の対応 本報告は本剤の安全性に影響を与えないと考えられるので、特段の措置はとらない。	公衆衛生 アメリカ

38



MMWR

Weekly

February 13, 2009 / 58(05);105-109

BENESIS2009-00

Increase in Coccidioidomycosis --- California, 2000--2007

Coccidioidomycosis is an infection resulting from inhalation of airborne spores of *Coccidioides immitis* or *Coccidioides posadasii*, soil-dwelling fungi endemic to California's San Joaquin Valley; southern regions of Arizona, Utah, Nevada, and New Mexico; western Texas; and regions of Mexico and Central and South America (1). Of an estimated 150,000 new infections annually in the United States (2), approximately 60% are asymptomatic (1). Patients with symptoms usually experience a self-limited influenza-like illness (ILI), although some develop severe pneumonia. Fewer than 1% of patients develop disseminated disease. Infection usually produces immunity to reinfection. During 1995--2000, the number of reported coccidioidomycosis cases in California averaged 2.5 per 100,000 population annually. However, from 2000 to 2006, the incidence rate more than tripled, increasing from 2.4 to 8.0 per 100,000 population. To characterize this increase, the California Department of Public Health (CDPH) analyzed case and hospitalization data for the period 2000--2007 and preliminary case report data for 2008. The results indicated that, during 2000--2006, the number of reported cases and hospitalizations for coccidioidomycosis in California increased each year, before decreasing in 2007. Annual incidence during 2000--2007 was highest in Kern County (150.0 cases per 100,000 population), and the hospitalization rate was highest among non-Hispanic blacks, increasing from 3.0 to 7.5 per 100,000 population. Health-care providers should maintain heightened suspicion for coccidioidomycosis in patients who live or have traveled in areas where the disease is endemic and who have signs of ILI, pneumonia, or disseminated infection.

Coccidioidomycosis is a reportable disease in California, although laboratories are not required to report. During 1991--1995, California experienced a large epidemic of coccidioidomycosis in the San Joaquin Valley; since 1995, cases of coccidioidomycosis have been reported consistently to local health departments in California using Confidential Morbidity Reports (CMRs). For the analysis summarized in this report, CDPH reviewed case and hospitalization data for the period 2000--2007 using CMRs and California Patient Discharge Data Set (CPDDS) data. Preliminary CMR case data for 2008 also were analyzed. CMRs include data on the patient's county of residence, sex, and dates of birth, illness onset, diagnosis, and case report. CPDDS data include inpatient discharge diagnoses from all California nonfederal hospitals. Cases with codes for coccidioidomycosis (114--114.5 and 114.9) from the *International Classification of Diseases, Ninth Edition* were selected. Duplicate records were removed so that the CMR data set retained only the first report of a case and the CPDDS retained only the first report of a patient's hospitalization. For the 3% of reported CMR cases with no date of illness onset or diagnosis, year of illness onset was presumed to be year of case report. CMR data were used to calculate incidence rates of reported cases overall and by age, sex, region, and county. Because 34% of reported CMR cases had missing data on race, incidence rates by race were not calculated. CPDDS data were used to calculate rates of first hospitalization overall and by age, sex, race/ethnicity, region, and county. California Department of Finance population projections were used for denominators (3). Negative binomial regression was used to test for statistical significance of change in rates of reported cases and hospitalizations during 2000--2006, the period of annual increase in reported cases and hospitalizations. Fatality rates among hospitalized patients were calculated by using CPDDS data for 2000--2007.

After remaining stable since 1995, reported coccidioidomycosis cases in California increased from 816 in 2000 (incidence rate: 2.4 per 100,000 population) to 2,981 in 2006 (8.0 per 100,000 population) ($p < 0.001$) (Figure 1), before decreasing in 2007 to 2,791 cases (7.4 per 100,000 population). Preliminary 2008 CMR data indicated that 1,718 cases were reported in California during January 1--December 6, 2008, compared with 2,210 and 2,426 cases reported during the same period in 2006 and 2007, respectively.

In California, coccidioidomycosis cases requiring hospitalization increased from 611 in 2000 (1.8 per 100,000 population) to 1,587 in 2006 (4.3 per 100,000 population) ($p < 0.001$), before decreasing to 1,368 (3.6 per 100,000 population) in 2007 (Figure 1). Hospitalizations for coccidioidomycosis were highest among persons aged 60--79 years, averaging 5.8 per 100,000 population during 2000--2007 (Table). By race/ethnicity, hospitalizations were highest among non-Hispanic blacks, compared with non-Hispanic whites, Hispanics, and Asians/Pacific Islanders. From 2000 to 2007, hospitalizations among non-Hispanic blacks increased from 66 (3.0 per 100,000 population) to 169 (7.5 per 100,000 population). Hospitalizations among non-Hispanic whites increased from 297 (1.9 per 100,000 population) in 2000 to 570 (3.5 per 100,000 population) in 2007; hospitalizations among Hispanics increased from 182 (1.6 per 100,000 population) to 485 (3.6 per 100,000 population), and hospitalizations among Asians/Pacific Islanders increased from 36 (0.9 per 100,000 population) to 86 (1.9 per 100,000 population).

By geographic region, hospitalizations for coccidioidomycosis in the San Joaquin Valley increased from 230 (6.9 per 100,000 population) in 2000 to 701 (17.7 per 100,000 population) in 2007. Within the region, Kern County reported the highest hospitalization rates, increasing from 121 (18.2 per 100,000 population) in 2000 to 285 (34.9 per 100,000 population) in 2007, and peaking in 2005 at 353 hospitalizations (45.8 per 100,000 population). Overall in California, during 2000--2007, a total of 752 (8.7%) of the 8,657 persons hospitalized for coccidioidomycosis died.

Reported by: DJ Vugia, MD, C Wheeler, MD, KC Cummings, MPH, California Dept of Public Health. A Karon, DVM, EIS Officer, CDC.

Editorial Note:

This report describes increases in reported coccidioidomycosis cases and hospitalizations during 2000--2007 and the highest incidence rate in California since 1995, the first year that CMR data were available consistently. The number of reported cases and hospitalizations decreased in 2007, and preliminary data indicate those decreases might have continued in 2008. However, rates of coccidioidomycosis in California remain substantially higher than during 1995--2000. These increased rates likely are real, rather than surveillance artifact, because no major changes in diagnosis or reporting of coccidioidomycosis in California occurred before or during the period studied.

Increases in coccidioidomycosis in California are similar to those observed in neighboring Arizona and in the United States overall. Arizona, which annually reports approximately 60% of all coccidioidomycosis cases in the United States, reported a substantial increase in coccidioidomycosis from 1,812 cases (37 per 100,000 population) in 1999 to 5,535 cases (91 per 100,000 population) in 2006 (4). In the United States overall, the number of reported coccidioidomycosis cases increased from 1,697 (0.64 per 100,000 population) in 1996 to 8,917 (6.79 per 100,000 population) in 2006 (5). Reasons for these recent increases in reported coccidioidomycosis are not fully understood. Some previous increases have been associated with local environmental and climatic variations (6). Other hypothesized causes include aerosolization of spores caused by soil disturbance during periods of increased construction activity (4), growing numbers of persons who are immunocompromised or have other risk factors for severe disease (7), and immigration of previously unexposed persons from areas where coccidioidomycosis is not endemic (2). Recent increases in coccidioidomycosis in California are partially attributable to several hundred cases reported from two San Joaquin Valley prisons (8) with inmates from areas where the disease is not endemic. Multiple clusters also have been reported at California military bases, where personnel often have intensive dust exposure (9). Such exposure is hypothesized to increase the risk for infection; local outbreaks of coccidioidomycosis have been noted after dust storms (1).

Coccidioidomycosis hospitalization rates in California were highest among persons aged 60--79 years, which is consistent with previous reports that older age might be a risk factor for severe coccidioidomycosis (7).

Hospitalization rates also were substantially higher among non-Hispanic blacks, compared with non-Hispanic whites, Hispanics, and Asians/Pacific Islanders. Black race has been associated previously with increased risk for coccidioidomycosis hospitalization (7). In addition, blacks and persons of Filipino ancestry have been found to have increased risk for disseminated coccidioidomycosis, possibly because of underlying differences in susceptible host genetics (1,10). Immunocompromised persons and women in their second and third trimesters of pregnancy also have increased risk for disseminated disease (1).

The findings in this report are subject to at least three limitations. First, because not all persons with coccidioidomycosis seek medical care and not all diagnosed cases are reported to local health departments, this report likely underestimates the actual rate of coccidioidomycosis in California. Second, for cases in which patients were hospitalized, medical chart review was not performed to confirm laboratory diagnosis or cause of death from coccidioidomycosis, resulting in possible overestimation of hospitalizations and deaths in persons with coccidioidomycosis diagnosed. Finally, Kern County's public health laboratory performs much of the coccidioidomycosis testing for patients in that county and might be more likely to report cases routinely than laboratories in most other counties in the San Joaquin Valley region where this is not the practice. In 2009, California plans to make coccidioidomycosis a laboratory-reportable disease to improve completeness and timeliness of case reporting and delivery of targeted public health recommendations during periods of increased disease.

Given the recent increases in coccidioidomycosis in California and Arizona, heightened consideration of this disease is warranted in the differential diagnosis of any patient with ILI, pneumonia, or signs of disseminated infection who has lived or traveled in areas where coccidioidomycosis is endemic. Because intensive dust exposure appears to increase the risk for infection, CDC recommends that persons living or traveling in regions where coccidioidomycosis is endemic who are at risk for severe or disseminated disease (e.g., older persons, pregnant women, immunocompromised persons, and persons of black race or Filipino ancestry) should avoid exposure to outdoor dust as much as possible.* When such exposure is unavoidable, measures to reduce inhalation of outdoor dust, such as wetting soil and using respiratory protection when engaging in soil-disturbing activities, might be effective. However, options for environmental control of coccidioidomycosis are limited, and no safe, effective vaccine for the disease exists currently. Developing such a vaccine appears to be the best option for preventing disease in those persons at risk for coccidioidomycosis (9).

Acknowledgments

The findings in this report are based, in part, on contributions by SR Bissell, MS, California Department of Health; and EC Weiss, MD, Office of Workforce and Career Development, CDC.


References

1. Chiller TM, Galgiani JN, Stevens DA. Coccidioidomycosis. *Infect Dis Clin N Am* 2003;17:41--57.
2. Galgiani JN, Ampel NM, Blair JE, et al. Coccidioidomycosis. *Clin Infect Dis* 2005;41:1217--23.
3. State of California Department of Finance. Race/ethnic population with age and sex detail, 1990--1999; 2000--2050. Sacramento, CA: State of California Department of Finance; July 2007.
4. Sunenshine RH, Anderson S, Erhart L, et al. Public health surveillance for coccidioidomycosis in Arizona. *Ann NY Acad Sci* 2007;1111:96--102.
5. CDC. Summary of notifiable diseases---United States, 2006. *MMWR* 2008;55.
6. Park BJ, Sigel K, Vaz V, et al. An epidemic of coccidioidomycosis in Arizona associated with climatic changes, 1998--2001. *J Infect Dis* 2005;191:1981--7.
7. Flaherman V, Hector R, Rutherford G. Estimating severe coccidioidomycosis in California. *Emerg Infect Dis* 2007;13:1087--9.
8. Pappagianis D. Coccidioidomycosis in California state correctional institutions. *Ann NY Acad Sci* 2007;1111:103--11.
9. Crum N, Lamb C, Utz G, Amundson D, Wallace M. Coccidioidomycosis outbreak among United States Navy SEALs training in a *Coccidioides immitis*--endemic area--Coalinga, California. *J Infect Dis* 2002;186:865--8.
10. Louie L, Ng S, Hajjeh R, et al. Influence of host genetics on the severity of coccidioidomycosis. *Emerg Infect Dis* 1999;5:672--80.

* Additional information available at <http://www.cdc.gov/travel/yellowbookch4-coccidioidomycosis.aspx>.

Figure 1

FIGURE 1. Rates* of reported cases of coccidioidomycosis and first hospitalizations among persons with coccidioidomycosis diagnosed — California, 1995–2007†




* Per 100,000 population.

† Data on reported cases of coccidioidomycosis are from California Department of Public Health Confidential Morbidity Reports; Data on first hospitalizations of persons with coccidioidomycosis diagnosed are from the California Patient Discharge Data Set. Population data are from California Department of Finance population projections.

[Return to top.](#)

Figure 2

FIGURE 2. Average annual rate* of reported cases of coccidioidomycosis, by county — California, 2000–2007†



* Per 100,000 population.

† Data on reported cases are from California Department of Public Health Confidential Morbidity Reports. County population data are from California Department of Finance population projections.

§ Kern County, located in the San Joaquin Valley region, where coccidioidomycosis is endemic, had the highest rate among counties (150.0 cases per 100,000 population).

[Return to top.](#)
Table

TABLE. Total numbers and average annual rates* of reported cases of coccidioidomycosis and first hospitalizations and deaths among persons with coccidioidomycosis diagnosed, by selected characteristics — California, 1995–1999 and 2000–2007†

Characteristic	1995–1999		2000–2007	
	No. of cases	Rate	No. of cases	Rate
Reported cases				
Age group (yrs)				
0–9	182	0.7	532	1.3
10–19	393	1.7	1,695	3.9
20–29	677	2.7	2,793	7.0
30–39	921	3.4	3,379	7.7
40–49	761	3.3	3,518	8.0
50–59	528	3.6	2,180	7.5
60–69	350	3.5	1,307	6.7
70–79	220	2.8	755	5.5
≥80	95	2.3	365	4.2
Sex				
Male	2,572	3.2	10,909	7.6
Female	1,529	1.9	5,848	4.0
Region				
California, overall	4,126	2.5	16,970	5.9
San Joaquin Valley§	2,829	17.9	12,855	44.1
Kern County	2,003	63.1	8,847	150.0
First hospitalizations				
Age group (yrs)				
0–9	47	0.2	151	0.4
10–19	148	0.6	361	0.8
20–29	348	1.4	853	2.1
30–39	574	2.1	1,409	3.2
40–49	709	3.1	1,851	4.2
50–59	609	4.1	1,690	5.1
60–69	509	5.0	1,130	5.8
70–79	439	5.6	785	5.8
≥80	170	4.2	427	5.0
Sex				
Male	2,237	2.8	5,960	4.1
Female	1,316	1.6	2,696	1.9
Region				
California, overall	3,553	2.2	8,657	3.0
San Joaquin Valley§	1,418	9.0	4,360	15.0
Kern County	704	22.2	2,206	37.4
Race/Ethnicity†				
Black, non-Hispanic	349	—	1,005	5.3
White, non-Hispanic	1,947	—	3,800	3.0
Hispanic	881	—	2,869	2.9
Asian/Pacific Islander	212	—	552	1.7
American Indian/Alaska Native	13	—	28	1.4
Multiracial/Other	80	—	192	3.4
Deaths	307	0.19	752	0.26

* Per 100,000 population.

† Data on reported cases are from California Department of Public Health Confidential Morbidity Reports. Data on first hospitalizations of persons with coccidioidomycosis diagnosed are from the California Patient Discharge Data Set. Denominator data are from California Department of Finance population projections.

§ Includes the following California counties: Fresno, Kern, Kings, Madera, Merced, San Joaquin, Stanislaus, and Tulare.

† Hospitalization rates by race/ethnic population could not be calculated for 1995–1999 because population estimates for this period included inconsistent race/ethnicity categories.

[Return to top.](#)

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in *MMWR* were current as of the date of publication.


All *MMWR* HTML versions of articles are electronic conversions from typeset documents. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (<http://www.cdc.gov/mmwr>) and/or the original *MMWR* paper copy for printable versions of official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.

**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.

Date last reviewed: 2/12/2009

[HOME](#) | [ABOUT MMWR](#) | [MMWR SEARCH](#) | [DOWNLOADS](#) | [RSS](#) | [CONTACT](#)
[POLICY](#) | [DISCLAIMER](#) | [ACCESSIBILITY](#)

SAFER • HEALTHIER • PEOPLE™
Morbidity and Mortality Weekly Report
Centers for Disease Control and Prevention
1600 Clifton Rd, MailStop E-90, Atlanta, GA 30333,
U.S.A.



B 個別症例報告概要

- 総括一覧表
- 報告リスト

個別症例報告のまとめ方について

個別症例報告が添付されているもののうち、個別症例報告の重複を除いたものを一覧表の後に添付した（国内症例については、資料3において集積報告を行っているため、添付していない）。

感染症定期報告の報告状況(2008/3/1~2009/5/29)

血対課ID	受理日	報告社名	一般名	生物由来成分名	原材料名	原産国	含有区分	文献	症例	措置報告
90097	2009/3/26	化学及血清療法研究所	乾燥抗破傷風人免疫グロブリン	抗破傷風人免疫グロブリン	ヒト血液	米国	有効成分	あり	なし	なし
90098	2009/3/17	日本メジフィック	放射性医薬品基準テクネチウム大凝集人血清アルブミン(99mTc)注射液	人血清アルブミン		日本	有効成分	なし	なし	なし
90099	2009/3/19	ベネシス	乾燥濃縮人アンチトロンピンIII	人血清アルブミン	ヒト血液	中国	製造工程	あり	なし	なし
90100	2009/3/19	ベネシス	乾燥濃縮人血液凝固第IV因子	人血清アルブミン	人血液	日本	有効成分添加物	あり	なし	なし
90101	2009/3/19	ベネシス	乾燥濃縮人血液凝固第IV因子	血液凝固第IV因子	人血液	日本	有効成分	あり	なし	なし
90102	2009/3/19	ベネシス	乾燥濃縮人血液凝固第IV因子	人免疫グロブリン	人血液	①日本、②米国、日本	有効成分	あり	なし	なし
90103	2009/3/26	日本製薬	乾燥ポリエチレングリコール処理人免疫グロブリン	人免疫グロブリン	人血液	日本	有効成分	あり	なし	なし
90104	2009/3/26	日本製薬	乾燥濃縮人アンチトロンピンIII	人アンチトロンピンIII	人血液	日本	有効成分	あり	なし	なし
90105	2009/3/26	日本製薬	乾燥濃縮人アンチトロンピンIII	トロンビン	トロンビン	日本	有効成分	あり	なし	なし
90106	2009/3/26	日本製薬	乾燥濃縮人血液凝固第IV因子	人血清アルブミン(20%) 加熱人血漿たん白 人血清アルブミン(25%) 人血清アルブミン(5%)	人血清アルブミン	人血液	日本	有効成分	あり	なし
90107	2009/3/27	化学及血清療法研究所	フィブリノゲン加第XIII因子	アプロチニン	ウシ肺臓	ウルグアイ、ニュージーランド	有効成分	なし	なし	なし
90108	2009/3/27	バクスター	乾燥人血液凝固因子抗体迂回活性複合体	乾燥濃縮人血液凝固因子	人血漿	米国	有効成分	あり	なし	なし
90109	2009/3/27	バクスター	乾燥濃縮人血液凝固因子	乾燥濃縮人血液凝固因子	人血漿	米国	有効成分	あり	あり	なし
90110	2009/3/27	バクスター	乾燥濃縮人血液凝固因子	乾燥濃縮人血液凝固因子	人血清アルブミン	人血漿	米国	添加物	あり	あり
90111	2009/3/27	CSLベリング	フィブリノゲン加第XIII因子	アプロチニン液	ウシ肺	ウルグアイ、ニュージーランド	有効成分	なし	なし	なし
90112	2009/3/27	CSLベリング	フィブリノゲン加第XIII因子	アンチトロンピン	ヒト血液	米国、ドイツ、オーストリア	製造工程	あり	あり	なし
90113	2009/3/27	CSLベリング	フィブリノゲン加第XIII因子	フィブリノゲン	ヒト血液	米国、ドイツ、オーストリア	有効成分	あり	なし	なし
90114	2009/3/27	CSLベリング	フィブリノゲン加第XIII因子	人血清アルブミン	ヒト血液	米国、ドイツ、オーストリア	有効成分添加物	あり	なし	なし
90115	2009/3/27	CSLベリング	フィブリノゲン加第XIII因子	トロンビン末	ヒト血液	米国、ドイツ、オーストリア	有効成分	あり	なし	なし
90116	2009/3/30	日本赤十字社	人血清アルブミン	人血清アルブミン	人血液	日本	有効成分	あり	なし	なし
90117	2009/4/1	化学及血清療法研究所	乾燥濃縮人血液凝固第IX因子	血液凝固第IX因子	ヒト血液	日本	有効成分	あり	なし	なし
90118	2009/4/15	化学及血清療法研究所	乾燥濃縮人アンチトロンピンIII	アンチトロンピンIII	ヒト血液	日本	有効成分	あり	あり	なし

90119	2009/4/15	化学及血清療法研究所	ヒスタミン加入免疫グロブリン製剤	免疫グロブリン	ヒト血液	日本	有効成分	あり	なし	なし
90120	2009/4/15	化学及血清療法研究所	乾燥濃縮人血液凝固第IX因子	乾燥濃縮人血液凝固第IX因子	マウス脾臓	日本	製造工程	なし	なし	なし
90121	2009/4/20	CSLベリング	フィブリノゲン加第XIII因子	人血液凝固第XIII因子	ヒト血液	米国、ドイツ、オーストリア	有効成分	あり	なし	なし
90122	2009/4/20	CSLベリング	乾燥pH4処理人免疫グロブリン	乾燥pH4処理人免疫グロブリン	ヒト血液	米国、ドイツ、オーストリア	製造工程	なし	なし	なし
90123	2009/4/20	CSLベリング	乾燥濃縮人血液凝固第IX因子	乾燥濃縮人血液凝固第IX因子	ヒト血液	米国、ドイツ、オーストリア	有効成分	あり	なし	なし
90124	2009/4/20	CSLベリング	乾燥濃縮人血液凝固第IX因子	乾燥濃縮人血液凝固第IX因子	ヒト血液	ドイツ	有効成分	あり	なし	なし
90125	2009/4/23	化学及血清療法研究所	フィブリノゲン加第XIII因子	フィブリノゲン加第XIII因子	ヒト血液	日本	有効成分	あり	なし	なし
90126	2009/4/23	化学及血清療法研究所	フィブリノゲン加第XIII因子	フィブリノゲン加第XIII因子	ヒト血液	日本	有効成分	あり	なし	なし
90127	2009/4/23	化学及血清療法研究所	乾燥濃縮人血液凝固第IX因子	乾燥濃縮人血液凝固第IX因子	ヒト血液	日本	製造工程	あり	なし	なし
90128	2009/4/23	化学及血清療法研究所	乾燥濃縮人血液凝固第IX因子	乾燥濃縮人血液凝固第IX因子	ヒト血液	日本	有効成分添加物	あり	あり	なし
90129	2009/4/23	化学及血清療法研究所	乾燥濃縮人血液凝固第IX因子	乾燥濃縮人血液凝固第IX因子	ヒト血液	日本	有効成分	あり	なし	なし
90130	2009/4/24	日本赤十字社	乾燥濃縮人血液凝固第IV因子	乾燥濃縮人血液凝固第IV因子	人血液	日本	有効成分	あり	なし	なし
90131	2009/4/24	日本赤十字社	乾燥濃縮人血液凝固第IV因子	乾燥濃縮人血液凝固第IV因子	人血清アルブミン	日本	添加物	あり	なし	なし
90132	2009/4/24	ベネシス	乾燥抗HBs人免疫グロブリン	乾燥抗HBs人免疫グロブリン	ヒト血液	米国	有効成分	あり	なし	なし
90133	2009/4/24	ベネシス	乾燥濃縮人血液凝固第IX因子	乾燥濃縮人血液凝固第IX因子	マウス脾臓	イギリス	製造工程	なし	なし	なし
90134	2009/4/24	ベネシス	乾燥濃縮人血液凝固第IX因子	乾燥濃縮人血液凝固第IX因子	ヒト血液	日本	製造工程	なし	なし	なし
90135	2009/4/24	日本メジフィック	放射性医薬品基準人血清アルブミン五酢酸テクネチウム(99mTc)注射液	放射性医薬品基準人血清アルブミン五酢酸テクネチウム(99mTc)	ヒト血液	日本	有効成分	なし	なし	なし
90136	2009/4/27	バイエル	乾燥濃縮人血液凝固第IX因子	乾燥濃縮人血液凝固第IX因子	ヒト血液	米国	製造工程	あり	なし	なし
90137	2009/4/27	バイエル	乾燥濃縮人血液凝固第IX因子	乾燥濃縮人血液凝固第IX因子	ヒト血液	米国	製造工程	あり	なし	なし
90138	2009/4/27	バイエル	乾燥濃縮人血液凝固第IX因子	乾燥濃縮人血液凝固第IX因子	ヒト血液	米国	製造工程	あり	なし	なし
90139	2009/4/27	バイエル	乾燥濃縮人血液凝固第IX因子	乾燥濃縮人血液凝固第IX因子	ヒト血液	米国	製造工程	あり	なし	なし
90140	2009/4/27	日本製薬	乾燥抗破傷風人免疫グロブリン	乾燥抗破傷風人免疫グロブリン	ヒト血液	米国	有効成分	あり	なし	なし
90141	2009/4/27	日本製薬	乾燥抗HBs人免疫グロブリン	乾燥抗HBs人免疫グロブリン	ヒト血液	米国	有効成分	あり	なし	なし
90142	2009/4/28	日本赤十字社	人免疫グロブリン	人免疫グロブリン	ヒト血液	日本	有効成分	あり	なし	なし
90143	2009/4/28	日本赤十字社	pH4処理酸性人免疫グロブリン	pH4処理酸性人免疫グロブリン	ヒト血液	日本	有効成分	あり	なし	あり
90144	2009/4/30	バクスター	乾燥濃縮人血液凝固第IX因子	乾燥濃縮人血液凝固第IX因子	ヒト血液	米国	有効成分	あり	なし	なし

感染症発生症例一覧

	番号	感染症の種類		発現国	性別	年齢	発現時期 (年/月/日)	転帰	出典	区分	備考
		器官別大分類	基本語								
第12回	0*	0	0	0	0	0	0	0	0	0	
第11回	11-1	臨床検査	C型肝炎ウイルス	ブラジル	男	不明	不明	不明	症例報告	外国製品	登録番号: 05000274 報告日: 2008年4月21日 MedDRA: Version (11.0)
	11-1	感染症および寄生虫症	HIV感染	ブラジル	男	不明	不明	死亡	症例報告	外国製品	登録番号: 05000274 報告日: 2008年4月21日 MedDRA: Version (11.0)
	11-2	臨床検査	C型肝炎ウイルス	ブラジル	男	不明	不明	死亡	症例報告	外国製品	登録番号: 07000030 報告日: 2008年3月5日 MedDRA: Version (11.0)
	11-2	感染症および寄生虫症	急性HIV感染	ブラジル	男	不明	不明	死亡	症例報告	外国製品	登録番号: 07000030 報告日: 2008年3月5日 MedDRA: Version (11.0)
第10回	10-1	臨床検査	C型肝炎ウイルス	ブラジル	男	小児	2004/5/25	不明	症例報告	外国製品	登録番号: 07000015 報告日: 2007年10月29日 MedDRA: Version (10.1)
	10-1	臨床検査	C型肝炎ウイルス	ブラジル	男	小児	2004/5/25	不明	症例報告	外国製品	登録番号: 07000015(追加報告) 報告日: 2007年12月28日 MedDRA: Version (10.1)
第9回	0*	0	0	0	0	0	0	0	0		

201

	番号	感染症の種類		発現国	性別	年齢	発現時期 (年/月/日)	転帰	出典	区分	備考
		器官別大分類	基本語								
第8回	0*	0	0	0	0	0	0	0	0	0	
第7回	0*	0	0	0	0	0	0	0	0	0	
第6回	0*	0	0	0	0	0	0	0	0	0	
第5回	5-1	感染症および寄生虫症	C型肝炎	フランス	男	不明	不明	不明	症例報告	外国製品	登録番号: 05000319(追加報告) 報告日: 2005年8月15日 MedDRA: Version (8.0)
	5-1	感染症および寄生虫症	C型肝炎	フランス	男	不明	不明	不明	症例報告	外国製品	登録番号: 05000319(完了報告) 報告日: 2005年7月27日 MedDRA: Version (8.0)

* 当該調査期間に対象となる感染症報告はなかった。

202

90108	2009/3/27	ボックス	乾燥人血液凝固因子抗体迂回活性複合体	乾燥人血液凝固因子抗体迂回活性複合体
-------	-----------	------	--------------------	--------------------

感染症発生症例一覧

Table with columns: 報告回, 番号, 感染症の種類 (器官別大分類, 基本語), 発現国, 性別, 年齢, 発現時期, 転帰, 出典, 区分, 鑑別番号, 報告日, MedDRA (Ver.), 備考. Contains 100 rows of infection case data.

感染症発生症例一覧

Table with columns: 報告回, 番号, 感染症の種類 (器官別大分類, 基本語), 発現国, 性別, 年齢, 発現時期, 転帰, 出典, 区分, 鑑別番号, 報告日, MedDRA (Ver.), 備考. Contains 100 rows of infection case data.

Table with columns: 報告回, 番号, 感染症の種類 (器官別大分類, 基本語), 発現国, 性別, 年齢, 発現時期, 転帰, 出典, 区分, 識別番号, 報告日, MedDRA (Ver.), 備考. Contains 40 rows of infection case data.

90109 2009/3/27 バクス 乾燥濃縮人血液凝固因子

Table with columns: 報告回, 番号, 感染症の種類 (器官別大分類, 基本語), 発現国, 性別, 年齢, 発現時期, 転帰, 出典, 区分, 識別番号, 報告日, MedDRA (Ver.), 備考. Contains 40 rows of infection case data, including a summary row with 0s.

